Hexarelin
Animal / preclinicalWADA prohibitedCommunity-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
The most potent of the classic growth-hormone-releasing peptides, with research interest extending to cardioprotective effects. Its trade-offs are known: it can raise cortisol/prolactin and receptors desensitise with continuous use, which shapes how the community cycles it.
Mechanism
Ghrelin-receptor agonist producing strong pituitary GH release; less selective than ipamorelin, so cortisol/prolactin can rise.
Evidence
Strong GH release is well documented and there is genuine cardiac research interest; physique outcomes haven't been formally trialled, and desensitisation is established.
Community-reported information
Community reports vary. Anecdotal and unvalidated; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
~1 hour.
Storage
Refrigerate lyophilised and reconstituted.
Commonly reported side effects
- Water retention
- Raised cortisol/prolactin
- Head-rush
Legal status by region
- USNot FDA-approved for human use.
- AUPrescription-only; import controlled.
Legal status changes over time; verify locally before relying on this.
Citations
- Hexarelin researchPubMed
- WADA Prohibited ListWADA